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Abstract 1 
Objective: Depression after stroke and myocardial infarction are common but often assumed to be 2 
undertreated without reliable evidence being available. Thus, we aimed to determine treatment rates 3 
and investigate the application of guidelines in these conditions. 4 
Methods: Databases MEDLINE, EMBASE, PsycInfo, Web of Science, CINAHL, and Scopus were 5 
systematically searched without language restriction from inception to 06/30/2017. Prospective 6 
observational studies with consecutive recruitment reporting any antidepressant treatment in adults 7 
with depression after stroke or myocardial infarction were included. Random effects models were 8 
used to calculate pooled estimates of treatment rates. 9 
Results: 55 studies reported 32 stroke cohorts (n = 8,938; pooled frequency of depression = 34%, 10 
95% CI 29 to 38%) and 17 myocardial infarction cohorts (n = 10,767; pooled frequency of 11 
depression = 24%, 95% CI 20 to 28%). In 29 stroke cohorts, 24% (95% CI 20 to 27%) of 2,280 12 
depressed people used antidepressant medication. In 15 myocardial infarction cohorts, 14% (95% CI 13 
8 to 19%) of 2,381 depressed people used antidepressant medication indicating a lower treatment 14 
rate than in stroke. After stroke, treatment with antidepressant medication was more frequent in 15 
moderate to severe (22%, 95% CI 14 to 29%) than in mild depression (9%, 95% CI 7 to 12%). Two 16 
studies reported use of psychosocial interventions, indicating that < 10% of participants were treated.  17 
Conclusions: Despite the high frequency of depression after stroke and myocardial infarction and 18 
the existence of efficacious treatment strategies, people often remain untreated. Strategies to increase 19 
the use of efficacious treatments are needed.  20 
 21 
Keywords: depression, stroke, myocardial infarction, treatment, pharmacoepidemiology 22 
 23 
 24 
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Introduction 1 
Stroke and myocardial infarction (MI) are among the most common causes of disability worldwide 2 
and their burden is likely to increase (1, 2). Both diseases share a sudden onset, a threat to life (3), a 3 
need for long term rehabilitation (4, 5), and similar lifestyle risk factors (6). Additionally, depression 4 
affects 31% of all people at any time up to five years after stroke (7) and 28% of all people within 5 
two years of MI (8). These conditions, referred to as post-stroke depression (PSD) and post-MI 6 
depression (PMID), have an adverse impact on rehabilitation, including impaired functional 7 
outcome, reduced quality of life, lower medication adherence, increased risk of recurrent events, and 8 
higher mortality (8-10). The efficacy of antidepressant drugs (ADTs), but not talking therapies, has 9 
been shown to be effective for the treatment of PSD, albeit with an associated increase in adverse 10 
events (11). People with PMID have been shown to benefit from ADTs and psychosocial 11 
interventions, including relaxation therapy (12, 13). Furthermore, ADTs are recommended in 12 
moderate to severe PSD and PMID while those with milder symptoms should be closely monitored 13 
(14, 15). Individual studies have also evaluated electroconvulsive therapy (11, 16), herbal medicine 14 
(14), and non-invasive brain stimulation (17), but their efficacy has not been comprehensively 15 
demonstrated.  16 
Proof of efficacy enhances the public’s beliefs about an intervention and thereby leads to better 17 
implementation (18). Nevertheless, use of ADTs is not a reliable indicator of adequate management 18 
of PSD. ADTs were found to reduce dependency, disability, neurological impairment, and pain after 19 
stroke which may be attributable to beneficial effects on drive and motivation as well as on central 20 
nervous functioning (19, 20). After MI, while  ADTs did not improvecould not be shown to improve 21 
cardiac prognosis (21-23) which may be due to low power for detecting mortality reduction in these 22 
trials (24). However, based on the current evidence people with depression after stroke may have 23 
some indications for the prescription of ADTs, which do not apply to MI. 24 Commented [SL3]: R2.C3 
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Despite the high frequency of PSD and PMID and the existence of efficacious treatment strategies, it 1 
is commonly stated that these patient groups are undertreated (25-30). However, studies rarely focus 2 
on the documentation of treatment rates resulting in a lack of comprehensive evidence. Therefore, we 3 
conducted a systematic review of the frequency of antidepressant treatment in people with PSD and 4 
PMID to determine the extent of undertreatment and to examine whether evidence-based 5 
recommendations are followed.  6 
Methods 7 
This systematic review was undertaken according to the MOOSE guidelines for meta-analyses of 8 
observational studies (31) and reported according to the PRISMA statement (32). The protocol was 9 
prospectively registered in PROSPERO (CRD42016051232).  10 
Study selection 11 
We included prospective observational studies with consecutive recruitment reporting data on 12 
treatment use at any given time-point after stroke or MI. Randomized controlled trials, case-control 13 
studies, and cross-sectional studies were excluded. Cohorts were included if participants (1) were ≥ 14 
18 years, (2) had a clinical diagnosis of stroke or MI, and (3) were assessed for depressive symptoms 15 
using defined scores on standard screening instruments or depressive disorders (minor depression, 16 
dysthymia, major depression) applying ICD or DSM criteria. Finally, studies were included if they 17 
(4) reported the frequency of use of ADTs, psychosocial interventions, herbal medicine, 18 
electroconvulsive therapy or non-invasive brain stimulation for the treatment of depression. 19 
Psychosocial interventions were defined as any treatment including telemedical or direct patient-20 
professional interaction ranging from counselling to psychotherapy. Interventions with the sole 21 
purpose of education, information or social transfer, and occupational therapy were excluded.  22 
 23 
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Data sources and extraction 1 
The literature search was conducted on MEDLINE, EMBASE, PsycInfo, Web of Science, CINAHL, 2 
and Scopus from inception to 06/30/2017. Databases were searched using MeSH terms and related 3 
keywords for stroke OR myocardial infarction AND depression AND prospective study design. The 4 
search strategy for MEDLINE is accessible at http://www.crd.york.ac.uk/PROSPEROFILES/ 5 
51232_STRATEGY_20161010.pdf and was adjusted for other databases. After searching and 6 
excluding irrelevant studies via title and abstract, eligibility was examined using full text articles. 7 
Reference lists of included articles and related review articles were manually searched. In an attempt 8 
to access all published studies worldwide, 17 non-English articles were reviewed in full text and 9 
translated from Chinese, Czech, Danish, French, German, Portuguese, Russian, and Spanish.  10 
Study quality was assessed by grouping studies into three categories representing completeness of 11 
case-selection (7). The ﬁrst group of population-based studies, considered the highest (least biased) 12 
quality, consisted of studies that attempted to recruit all people with stroke or MI, including those not 13 
admitted to hospital for acute care. The other two categories were hospital-based studies, which 14 
included all inpatients recruited from acute care medical wards in general hospitals, and 15 
rehabilitation-based studies, which included patients from rehabilitation wards or stroke/cardiac care 16 
units. Treatment rates were also pooled and compared among WHO world regions (33) and between 17 
OECD-member and non-member countries, if applicable. Furthermore, treatment rates were pooled 18 
and compared among decades of publication (before 2000, 2000-2009, since 2010). 19 
Study reports with evidence of overlapping recruitment sites, study dates, grant funding numbers, 20 
and similar or identical reported patient characteristics were considered to be from the same cohort. 21 
If several articles reported data from the same cohort, data were taken from the first publication of a 22 
given time-point. If multiple instruments were used to assess depressive symptoms and their 23 
treatment at the same time point, data showing the highest proportion treated were included.  24 
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All authors were contacted for missing or additional data and to confirm suspected overlapping 1 
cohorts. Additional data were included if received before 30/09/2017. 2 
Data synthesis 3 
Extracted data were stratified according to case selection and time of assessment after stroke or MI. 4 
Data assessed up to three months after the ictus were categorized as short-term, from three up to 5 
twelve months as medium-term and twelve months or later as long-term. Depression was categorised 6 
as mild (minor, mild depression; dysthymia) or moderate/severe (moderate, severe, major 7 
depression) according to the categories applied by study authors.  8 
Frequencies of depressive symptoms and treatment use at the first assessment were pooled using the 9 
random effects model of DerSimonian and Laird (34). Sensitivity analyses included the comparison 10 
with fixed effect models, treatment use at last assessment, cohort size: small (n < 100) and large (n > 11 
100), and interviewer-administered vs. self-completed questionnaires to screen for depression. 12 
Publication bias was assessed by inspecting funnel plots and conducting Egger’s regression (35). 13 
Subgroup meta-analyses included patient groups with mild, moderate/severe, and no depression 14 
receiving treatment.  15 
Results 16 
The applied search strategies identified over 46,000 articles, of which 625 were reviewed in full-text. 17 
32 stroke and 17 MI studies (in 55 manuscripts) were included. Authors of 20 studies provided 18 
additional unpublished data (36-55). The review process is illustrated in Figure 1.  19 
 20 
------------------- INSERT [FIG. 1] ABOUT HERE------------------ 21 
 22 
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Description of the study samples Population description 1 
People with stroke were assessed between two weeks and five years after the ictus. The minimum 2 
age criterion of ≥ 18 years could not be confirmed in seven studies (56, 66, 67, 71, 74-76). One study 3 
(59) included people ≥ 15 years of age and was included because of an assumed small number of 4 
people under 18 years and a large sample size. Further study details are listed in Table 1. The pooled 5 
frequency of PSD in 32 cohorts was 34% (95% confidence interval [CI] 29 to 38%) with significant 6 
heterogeneity among studies (p < .001) and a significant intercept in Egger’s regression (p < .001) 7 
indicating that smaller studies reported higher frequencies.  8 
 9 
------------------- INSERT [TABLE 1] ABOUT HERE------------------ 10 
 11 
People with MI were assessed between one day and 18 months after the ictus. The age criterion 12 
could not be confirmed in three studies (79, 82, 84). Further study details are listed in Table 2. The 13 
pooled frequency of PMID in 17 cohorts was 24% (95% CI 20 to 28%) with significant 14 
heterogeneity (p < .001) and a non-significant intercept in Egger’s regression (p = .19). 15 
 16 
------------------- INSERT [TABLE 2] ABOUT HERE------------------ 17 
 18 
Treatment of PSD 19 
No treatment other than ADTs or psychosocial interventions were reported. One stroke study 20 
reported use of psychotherapy (none of the 89 people with PSD received psychotherapy) (60), and 21 
another reported if people were referred to a psychiatric service in addition to receiving ADTs (none 22 
of 11 people with PSD were referred) (41). The studies did not specify these treatments further. 23 
Hence, 31 studies reported use of ADTs. One of these did not report the cut-off used for depression 24 
Commented [LS4]: J.C3 
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assessment and was excluded from analyses (55). Visual investigation of the funnel plot led to 1 
exclusion of a further study representing an outlier with small sample (62). Results of sensitivity 2 
analyses were identical if this study was in- or excluded. 3 
Finally, 29 cohorts consisting of 8,634 people with stroke were included in random effects analyses 4 
of ADT use. Frequency of PSD in these cohorts (32%, 95% CI 27 to 37%) was not significantly 5 
different from the frequency in all 32 cohorts. The pooled estimate of ADT use was 24% (95% CI 20 6 
to 27%) in 2,280 people with PSD with significant heterogeneity among studies (p < .001) and a 7 
non-significant intercept in Egger’s regression (p = .082). Sensitivity analyses did not produce any 8 
significantly different result. The forest plot (Fig. 2) illustrates the pooled estimates for different time 9 
windows and recruitment types. There was no significant difference in treatment rates among 10 
population-based (21%, 95% CI 14 to 28%), hospital-based (21%, 95% CI 15 to 27%), and 11 
rehabilitation-based studies (28%, 95% CI 22 to 34%). Analyses comparing pooled treatment rates 12 
between cohorts from different WHO world regions (33),between OECD member and non-member 13 
countries as well as among decades of publication produced no significantly different results.  14 
 15 
------------------- INSERT [FIG. 2] ABOUT HERE------------------ 16 
 17 
Data on ADT use could be extracted from three cohorts with mild depression (41, 42, 71) and six 18 
cohorts with moderate to severe depression (37, 39, 41, 42, 67, 71). ADTs were significantly less 19 
often used in PSD with mild depression (9%, 95% CI 7 to 12%) than in PSD with moderate to severe 20 
depression (22%, 95% CI 14 to 29%). Heterogeneity of studies was not significant in either group (p 21 
> .30). 22 
Furthermore, twelve studies reported ADT use in non-depressed people with stroke (39-41, 54, 57, 23 
58, 64, 69-71, 75, 77). The pooled estimate of these frequencies was 11% (95% CI 7 to 14%) with 24 
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significant heterogeneity among studies (p < .001) and a non-significant intercept in Egger’s 1 
regression (p > .90). Additionally, one study reported that 18% of those not depressed and treated at 2 
12 months were previously depressed at 3 months (57) and one study reported that 64% who were 3 
not depressed and treated at 6 months were previously depressed at 7 weeks (54).  4 
Treatment of PMID 5 
No treatment other than ADTs or psychosocial interventions were reported. One study reported the 6 
use of psychopharmacology and/or psychotherapy by 3 of 5 with PMID (60.0%) (78), one study 7 
reported use of psychiatric treatment by 3 of 18 with PMID (16.6%) (82), and one study reported use 8 
of psychosocial interventions for depression by 72 of 759 with PMID (9.5%) (81) without further 9 
description of these interventions.  10 
The 15 studies reporting use of ADTs consisted of 10,635 with MI who were included in the random 11 
effects analyses. The pooled frequency of PMID in these cohorts (25%, 95% CI 21 to 30%) was not 12 
significantly different from the frequency in all 17 cohorts. The pooled frequency of ADT use was 13 
14% (95% CI 8 to 19%) in 2,381 with PMID and hence, significantly lower than in PSD. 14 
Heterogeneity among studies was significant (p < .001) with a non-significant intercept in Egger’s 15 
regression (p = .062). The estimate did not change in sensitivity analyses. Furthermore, people in 16 
hospital-based studies received ADTs more often (19%, 95% CI 15 to 24%) than people in 17 
rehabilitation-based studies (8%, 95% CI 4 to 13%). The ten short-term studies showed a pooled 18 
frequency of 16% (95% CI 11 to 21%) (44, 45, 48-53, 80, 81), the three medium-term studies a 19 
frequency of 12% (95% CI 0 to 25%) (46, 83, 84), and the two long-term studies a frequency of 6% 20 
(95% CI 1 to 10%) (47, 79) demonstrating a significant difference between frequencies in the short- 21 
and the two long-term rehabilitation-based studies. Comparing pooled treatment rates between 22 
cohorts from the European region and the region of the Americas as well as among decades of 23 
publication yielded no significant difference.  24 
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Discussion 1 
This meta-analysis provides the first comprehensive evidence of depression treatment rates after 2 
stroke and myocardial infarction. Although more PSD cohorts could be identified, PMID cohorts 3 
were usually larger resulting in similar numbers of people being included. The frequencies of 4 
depressive symptoms were in the same range as in other systematic reviews on PSD (7) and PMID 5 
(8), supporting the generalisability of our findings. Only a few study authors reported the use of 6 
treatments other than ADTs (41, 60, 78, 81, 82). This may be explained by the lack of evidence of 7 
other efficacious treatments for people with PSD (11), whereas pharmacological and psychological 8 
psychosocial interventions have proven efficacious for PMID (12). This may also be due to the 9 
investigation of more innovative interventions in PMID like  e.g. the telephone-based collaborative 10 
care program of the MOSAIC trial (85).  As only few or no people used psychosocial interventions 11 
in the studies reporting these treatments and use of psychosocial interventions may be documented 12 
less often in outpatient settings, this finding may also be attributed to reporting and measurement 13 
biases.  14 
Every fourth person with PSD and every seventh person with PMID reported using ADTs indicating 15 
that only a small proportion of people with depression after stroke and MI receives evidence-based 16 
treatment. Clinical trials have proven the efficacy of ADTs in both disorders (11, 12) but they are 17 
only effective if they are prescribed and taken (18). Additionally, some studies indicate higher 18 
mortality in people with untreated PSD and PMID (81, 86). However, the ENRICHD trial did not 19 
show a reduction of late mortality in people with PMID who were treated with cognitive behavioral 20 
therapy and sertraline but demonstrated increased late mortality in people whose depression is 21 
refractory to treatment (22). Possible reasons for undertreatment include insufficient assessment and 22 
follow-up of psychological status (47, 87) as well as uncertainty due to comorbidities and 23 
polypharmacy, which is common in people with stroke and MI (25).  Furthermore,  depression may 24 
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be perceived as a natural reaction to stroke or MI which therefore is assumed to require no further 1 
treatment (88). Depressive symptoms such as lack of energy, hopelessness and withdrawal may also 2 
contribute to people stopping rehabilitation, follow-up visits and medications (46). Additionally, 3 
patients may want to avoid the label and associated stigma of mental illness and therefore,  withdraw 4 
from treatment (89).  Frequency of treatment was not different based on case selection in PSD, 5 
indicating similar health care practices across all settings. Treatment rates in rehabilitation-based 6 
PMID cohorts were significantly lower than in hospital-based cohorts, which contrasts especially 7 
with stroke cohorts showing the descriptively highest frequency of treatment in rehabilitation 8 
settings. The difference between MI cohorts may be attributable to better access of people with MI to 9 
mental health professionals in hospital compared to rehabilitation due to counselcil service. Although 10 
guidelines list psychological evaluation as an essential part of cardiac rehabilitation (84), evidence 11 
suggests low psychological expertise in this setting (85). While cardiac rehabilitation usually focuses 12 
on the prevention of recurrent events using pharmacological and lifestyle interventions (84), stroke 13 
rehabilitation includes neuropsychological assessment and treatment of cognitive impairment (86). 14 
Therefore, mental health expertise may be higher in hospital and stroke rehabilitation compared to 15 
cardiac rehabilitation possibly resulting in better recognition and treatment of depressive symptoms. 16 
Treatment rates in PSD and PMID did not differ between world regions (33) or by OECD 17 
membership where most cohorts were from Europe, North America and/or OECD countries. 18 
Additionally, treatment rates did not differ depending on year of publication despite major 19 
developments in the health care of people with stroke and MI over the last decades. Three studies 20 
(37, 40, 69) distinguishing classes of ADTs reported SSRIs being most frequently used in PSD 21 
which is in line with research favoring SSRIs as a pharmacological treatment (19). 22 
PSD was more frequently treated than PMID and a tenth of non-depressed people received ADTs 23 
after stroke. This may be based on the clinical consideration of findings supporting the efficacy of 24 
Commented [SL7]: R2.C1 
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ADTs for physical and functional rehabilitation after stroke (19, 20). Additionally, people with more 1 
severe PSD received ADTs more frequently which is in keeping with evidence-based guideline 2 
recommendations (15), better recognition (90), and higher need (91). 3 
While our findings are limited by the high variability of the assessment tools used, criteria for 4 
depressive symptoms, assessment times, methods for collecting data on treatment use, and the 5 
selection criteria within the cohorts, they remain consistent in sensitivity analyses. As a further 6 
strength of this meta-analysis, we included many unpublished data sets which were provided by 7 
original authors. However, it must be noted that the reported use of antidepressants may not indicate 8 
adequate treatment of depression as they may also be described to improve physical and functional 9 
rehabilitation or treat anxiety (19, 20). Furthermore, this meta-analysis excluded interventions solely 10 
providing information or education as they were not investigated in randomized controlled trials up 11 
to now. Nevertheless, people with PSD or PMID may benefit from these interventions. Finally, many 12 
cohorts had to be excluded as they assessed depressive symptoms in cohorts of people with coronary 13 
diseases generally, rather than solely MI. We are unclear if, or to what extent, this may bias our 14 
results. 15 
While the specific determinants of treatment use in PSD and PMID may need further investigation, 16 
the considerable undertreatment found in our study indicates a need for screening for depression after 17 
stroke and MI (8, 9) and clear management protocols which include reassessment and stopping 18 
guidelines for use in healthcare settings. As guidelines already include similar recommendations (9, 19 
14, 15), specific education of health professionals is essential to close the gap to clinical practice, 20 
increase treatment rates,  and thereby reduce the significant burden of PSD and PMID globally (1).   21 
Commented [LS8]: J.C4 
Commented [LS9]: R2.C2 
Treatment rates in PSD and PMID 
 
15 
 
Acknowledgments 1 
The authors would like to thank all corresponding study authors for providing additional data and 2 
information. We also thank Mansur Kutlubaev (Russian), Lorena Ataíde Lopes (Portuguese), and 3 
Marek Čontošfalský (Czech) for translating non-English language articles.  4 
 5 
  6 
Treatment rates in PSD and PMID 
 
16 
 
Figure captions 1 
 2 
Fig.1 PRISMA flow diagram of literature review process 3 
Fig.2 Forest plot of antidepressant drug treatment in people with post-stroke depression  4 
 5 
 6 
 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
   
 
  17 
 
References 
1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 
2030. PLoS Med. 2006;3:e442. 
2. Truelsen T, Piechowski‐Jóźwiak B, Bonita R, Mathers C, Bogousslavsky J, Boysen G. Stroke 
incidence and prevalence in Europe: a review of available data. Eur J Neurol. 2006;13:581-98. 
3. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal 
R, Ahn SY, al e. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 
2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013;380:2095-128. 
4. Duncan PW, Zorowitz R, Bates B, Choi JY, Glasberg JJ, Graham GD, Katz RC, Lamberty K, Reker 
D. Management of adult stroke rehabilitation care: A clinical practice guideline. Stroke. 2005;36:e100-
e43. 
5. O'Gara PT, Kushner F, Ascheim D, Casey DJ, Chung M, de Lemos J, Ettinger S, Fang J, Fesmire 
F, Franklin B, Granger C, Krumholz H, Linderbaum J, Morrow D, Newby L, Ornato J, Ou N, Radford M, 
Tamis-Holland J, Tommaso C, Tracy C, Woo Y, Zhao D. ACCF/AHA guideline for the management of ST-
elevation myocardial infarction: Executive Summary: A report of the American College of Cardiology 
Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:529-
55. 
6. Aben I, Verhey F, Strik J, Lousberg R, Lodder J, Honig A. A comparative study into the one year 
cumulative incidence of depression after stroke and myocardial infarction. J Neurol Neurosurg 
Psychiatry. 2003;74:581-5. 
7. Hackett ML, Pickles K. Part I: Frequency of depression after stroke: A updated systematic 
review and meta‐analysis of observational studies. International Journal of Stroke. 2014;9:1017-25. 
8. Meijer A, Conradi HJ, Bos EH, Thombs BD, van Melle JP, de Jonge P. Prognostic association of 
depression following myocardial infarction with mortality and cardiovascular events: A meta-analysis 
of 25 years of research. Gen Hosp Psychiatry. 2011;33:203-16. 
9. Towfighi A, Ovbiagele B, El Husseini N, Hackett ML, Jorge RE, Kissela BM, Mitchell PH, Skolarus 
LE, Whooley MA, Williams LS. Poststroke depression: A scientific statement for healthcare 
professionals from the American Heart Association/American Stroke Association. Stroke. 
2017;48:e30-e43. 
10. Gehi AK, Ali S, Na B, Whooley MA. Self-reported medication adherence and cardiovascular 
events in patients with stable coronary heart disease: The heart and soul study. Arch Intern Med. 
2007;167:1798-803. 
11. Hackett ML, Anderson CS, House A, Xia J. Interventions for treating depression after stroke. 
Cochrane Libr. 2008. 
12. Baumeister H, Hutter N, Bengel J. Psychological and pharmacological interventions for 
depression in patients with coronary artery disease. Cochrane Libr. 2011. 
13. van Dixhoorn J, White A. Relaxation therapy for rehabilitation and prevention in ischaemic 
heart disease: a systematic review and meta-analysis. Eur J Cardiovasc Prev Rehabil. 2005;12:193-202. 
14. Lichtman JH, Bigger JT, Blumenthal JA, Frasure-Smith N, Kaufmann PG, Lespérance F, Mark 
DB, Sheps DS, Taylor CB, Froelicher ES. Depression and coronary heart disease. Circulation. 
2008;118:1768-75. 
15. Lindsay P, Bayley M, Hellings C, Hill M, Woodbury E, Phillips S. Canadian best practice 
recommendations for stroke care (updated 2008). CMAJ. 2008;179:S1-S25. 
16. Grover S, Suchendra K, Mehra A, Parkash V, Saini V, Bagga S. Use of electroconvulsive therapy 
in an elderly after 5 weeks of myocardial infraction with 30% cardiac output. Ind Psychiatry J. 
2015;24:195-7. 
17. Bueno VF, Brunoni AR, Boggio PS, Bensenor IM, Fregni F. Mood and cognitive effects of 
transcranial direct current stimulation in post-stroke depression. Neurocase. 2011;17:318-22. 
   
 
  18 
 
18. Jorm AF, Medway J, Christensen H, Korten AE, Jacomb PA, Rodgers B. Public beliefs about the 
helpfulness of interventions for depression: Effects on actions taken when experiencing anxiety and 
depression symptoms. Aust N Z J Psychiatry. 2000;34:619-26. 
19. Mead GE, Hsieh C-F, Lee R, Kutlubaev M, Claxton A, Hankey GJ, Hackett M. Selective serotonin 
reuptake inhibitors for stroke recovery. Stroke. 2013;44:844-50. 
20. Hesami O, Gharagozli K, Beladimoghadam N, Assarzadegan F, Mansouri B, Sistanizad M. The 
efficacy of gabapentin in patients with central post-stroke pain. Iran J Pharm Res. 2015;14:95-101. 
21. Van Melle JP, De Jonge P, Honig A, Schene AH, Kuyper AM, Crijns HJ, Schins A, Tulner D, Ormel 
J. Effects of antidepressant treatment following myocardial infarction. The British Journal of 
Psychiatry. 2007;190:460-6. 
22. Carney RM, Blumenthal JA, Freedland KE, Youngblood M, Veith RC, Burg MM, Cornell C, Saab 
PG, Kaufmann PG, Czajkowski SM. Depression and late mortality after myocardial infarction in the 
Enhancing Recovery in Coronary Heart Disease (ENRICHD) study. Psychosom Med. 2004;66:466-74. 
23. Glassman AH, Bigger JT, Gaffney M. Psychiatric characteristics associated with long-term 
mortality among 361 patients having an acute coronary syndrome and major depression: Seven-year 
follow-up of SADHART participants. Arch Gen Psychiatry. 2009;66:1022-9. 
24. Joynt KE, O'Connor CM. Lessons from SADHART, ENRICHD, and other trials. Psychosom Med. 
2005;67:S63-S6. 
25. Gaete JM, Bogousslavsky J. Post-stroke depression. Expert Rev Neurother. 2008;8:75-92. 
26. Celano CM, Huffman JC. Depression and cardiac disease: A review. Cardiol Rev. 2011;19:130-
42. 
27. House A. Depression after stroke. Br Med J (Clin Res Ed). 1987;294:76-8. 
28. Lindén T, Blomstrand C, Skoog I. Depressive disorders after 20 months in elderly stroke 
patients. Stroke. 2007;38:1860-3. 
29. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular 
disease: epidemiology, biology, and treatment. Arch Gen Psychiatry. 1998;55:580-92. 
30. Sundquist K, Chang BP, Parsons F, Dalrymple N, Edmondson D, Sumner JA. Treatment rates 
for PTSD and depression in recently hospitalized cardiac patients. J Psychosom Res. 2016;86:60-2. 
31. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe 
TA, Thacker SB. Meta-analysis of observational studies in epidemiology: A proposal for reporting. J Am 
Med Assoc. 2000;283:2008-12. 
32. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews 
and meta-analyses: The PRISMA statement. Ann Intern Med. 2009;151:264-9. 
33. (WHO) WHO. List of WHO member states and respective world region. 2017 [11/22/2017]; 
Available from: http://www.who.int/choice/demography/regions/en/. 
34. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88. 
35. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, 
graphical test. Br Med J. 1997;315:629-34. 
36. Paolucci S, Gandolfo C, Provinciali L, Torta R, Toso V, Group tDS. The Italian multicenter 
observational study on post–stroke depression (DESTRO). J Neurol. 2006;253:556-62. 
37. Ayis SA, Ayerbe L, Crichton SL, Rudd AG, Wolfe CDA. The natural history of depression and 
trajectories of symptoms long term after stroke: The prospective south London stroke register. J Affect 
Disord. 2016;194:65-71. 
38. Townend B, Whyte S, Desborough T, Crimmins D, Markus R, Levi C, Sturm J. Longitudinal 
prevalence and determinants of early mood disorder post-stroke. J Clin Neurosci. 2007;14:429-34. 
39. Townend E, Tinson D, Kwan J, Sharpe M. 'Feeling sad and useless': An investigation into 
personal acceptance of disability and its association with depression following stroke. Clin Rehabil. 
2010;24:554-64. 
40. Appelros P, Viitanen M. Prevalence and predictors of depression at one year in a Swedish 
population-based cohort with first-ever stroke. J Stroke Cerebrovasc Dis. 2004;13:52-7. 
   
 
  19 
 
41. Sharpe M, Hawton K, Seagroatt V, Bamford J, House A, Molyneux A, Sandercock P, Warlow C. 
Depressive disorders in long-term survivors of stroke: Associations with demographic and social 
factors, functional status, and brain lesion volume. Br J Psychiatry. 1994;164:380-6. 
42. Skånér Y, Nilsson GH, Sundquist K, Hassler E, Krakau I. Self-rated health, symptoms of 
depression and general symptoms at 3 and 12 months after a first-ever stroke: A municipality-based 
study in Sweden. BMC Fam Pract. 2007;8. 
43. Tene O, Shenhar-Tsarfaty S, Korczyn AD, Kliper E, Hallevi H, Shopin L, Auriel E, Mike A, 
Bornstein NM, Assayag EB. Depressive symptoms following stroke and transient ischemic attack: Is it 
time for a more intensive treatment approach? results from the TABASCO cohort study. J Clin 
Psychiatry. 2016;77:673-80. 
44. Celano CM, Beale EE, Beach SR, Belcher AM, Suarez L, Motiwala SR, Gandhi PU, Gaggin H, 
Januzzi Jr JL, Healy BC. Associations between pychological constructs and cardiac biomarkers after 
acute coronary syndrome. Psychosom Med. 2017;79:318-26. 
45. Frasure-Smith N, Lespérance F, Talajic M. Depression following myocardial infarction: impact 
on 6-month survival. J Am Med Assoc. 1993;270:1819-25. 
46. Grace SL, Abbey SE, Pinto R, Shnek ZM, Irvine J, Stewart DE. Longitudinal course of depressive 
symptomatology after a cardiac event: Effects of gender and cardiac rehabilitation. Psychosom Med. 
2005;67:52-8. 
47. Grace SL, Leung YW, Stewart DE. A prospective examination of antidepressant use and its 
correlates in patients with acute coronary syndrome. Psychosomatics. 2008;49:199-207. 
48. Huffman JC, Smith FA, Blais MA, Beiser ME, Januzzi JL, Fricchione GL. Recognition and 
treatment of depression and anxiety in patients with acute myocardial infarction. Am J Cardiol. 
2006;98:319-24. 
49. Kroemeke A. Depressive symptom trajectories over a 6-year period following myocardial 
infarction: Predictive function of cognitive appraisal and coping. J Behav Med. 2016;39:181-91. 
50. Kuhlmann SL, Tschorn M, Arolt V, Beer K, Brandt J, Grosse L, Haverkamp W, Müller-Nordhorn 
J, Rieckmann N, Waltenberger J. Serum brain-derived neurotrophic factor and stability of depressive 
symptoms in coronary heart disease patients: A prospective study. Psychoneuroendocrinology. 
2017;77:196-202. 
51. Parakh K, Thombs BD, Fauerbach JA, Bush DE, Ziegelstein RC. Effect of depression on late (8 
years) mortality after myocardial infarction. Am J Cardiol. 2008;101:602-6. 
52. Rothenbacher D, Jaensch A, Mons U, Hahmann H, Becker T, Koenig W, Brenner H. Prognostic 
value of one-year course of symptoms of anxiety and depression in patients with coronary heart 
disease: Role of physical activity and unmet medical need. Eur J Prev Cardiol. 2015;22:1129-38. 
53. Schlyter M, Östman M, Engström G, André-Petersson L, Tydén P, Leosdottir M. Personality 
factors and depression as predictors of hospital-based health care utilization following acute 
myocardial infarction. Eur J Cardiovasc Nurs. 2017;16:318-25. 
54. Volz M, Möbus J, Letsch C, Werheid K. The influence of early depressive symptoms, social 
support and decreasing self-efficacy on depression 6 months post-stroke. Journal of Affective 
Disorders. 2016;206:252-5. 
55. Carod-Artal J, Egido JA, González JL, De Seijas EV. Quality of life among stroke survivors 
evaluated 1 year after stroke: Experience of a stroke unit. Stroke. 2000;31:2995-3000. 
56. Ebrahim S, Barer D, Nouri F. Affective illness after stroke. Br J Psychiatry. 1987;151:52-6. 
57. El Husseini N, Goldstein LB, Peterson ED, Zhao X, Pan W, Olson DM, Zimmer LO, Williams JW, 
Bushnell C, Laskowitz DT. Depression and antidepressant use after stroke and transient ischemic 
attack. Stroke. 2012;43:1609-16. 
58. Kauhanen M, Korpelainen J, Hiltunen P, Brusin E, Mononen H, Määttä R, Nieminen P, 
Sotaniemi K, Myllylä V. Poststroke depression correlates with cognitive impairment and neurological 
deficits. Stroke. 1999;30:1875-80. 
59. Kotila M, Numminen H, Waltimo O, Kaste M. Post‐stroke depression and functional recovery 
in a population‐based stroke register. The Finnstroke study. Eur J Neurol. 1999;6:309-12. 
   
 
  20 
 
60. Paolucci S, Di Vita A, Massicci R, Traballesi M, Bureca I, Matano A, Iosa M, Guariglia C. Impact 
of participation on rehabilitation results: A multivariate study. Eur J Phys Rehabil Med. 2012;48:455-
66. 
61. Pohjasvaara T, Leppävuori A, Siira I, Vataja R, Kaste M, Erkinjuntti T. Frequency and clinical 
determinants of poststroke depression. Stroke. 1998;29:2311-7. 
62. Cassidy EM, O'Connor R, O'Keane V. Prevalence of post-stroke depression in an Irish sample 
and its relationship with disability and outcome following inpatient rehabilitation. Disabil Rehabil. 
[Article]. 2004;26:71-7. 
63. De Ryck A, Fransen E, Brouns R, Geurden M, Peij D, Mariën P, De Deyn PP, Engelborghs S. 
Psychosocial problems associated with depression at 18 months poststroke. Int J Geriatr Psychiatry. 
2014;29:144-52. 
64. Desmaele S, Putman K, De Wit L, Dejaeger E, Gantenbein AR, Schupp W, Steurbaut S, Dupont 
AG, De Paepe K. A comparative study of medication use after stroke in four countries. Clin Neurol 
Neurosurg. [Article]. 2016;148:96-104. 
65. Jürgensen F, Meins W, Meier-Baumgartner HP. Depression after stroke: Prevalence, 
functional outcome and recovery six months after discharge from a geriatric rehabilitation center. Z 
Gerontol Geriatr. 1999;32:251. 
66. Naess H, Lunde L, Brogger J. The triad of pain, fatigue and depression in ischemic stroke 
patients: The Bergen Stroke Study. Cerebrovasc Dis. 2012;33:461-5. 
67. Nys G, Van Zandvoort M, Van der Worp H, De Haan E, De Kort P, Kappelle L. Early depressive 
symptoms after stroke: Neuropsychological correlates and lesion characteristics. J Neurol Sci. 
2005;228:27-33. 
68. van de Weg F, Kuik D, Lankhorst G. Post-stroke depression and functional outcome: A cohort 
study investigating the influence of depression on functional recovery from stroke. Clin Rehabil. 
1999;13:268-72. 
69. Verdelho A, Henon H, Lebert F, Pasquier F, Leys D. Depressive symptoms after stroke and 
relationship with dementia: A three-year follow-up study. Neurology. 2004;62:905-11. 
70. Paul SL, Dewey HM, Sturm JW, Macdonell RA, Thrift AG. Prevalence of depression and use of 
antidepressant medication at 5-years poststroke in the North East Melbourne Stroke Incidence Study. 
Stroke. 2006;37:2854-5. 
71. Loong CK, Kenneth NKC, Paulin ST. Post-stroke depression: Outcome following rehabilitation. 
Aust N Z J Psychiatry. 1995;29:609-14. 
72. Saxena S, Ng T, Yong D, Fong N, Koh G. Subthreshold depression and cognitive impairment but 
not demented in stroke patients during their rehabilitation. Acta Neurol Scand. 2008;117:133-40. 
73. Shi YZ, Xiang YT, Wu SL, Zhang N, Zhou J, Bai Y, Wang S, Wang YL, Zhao XQ, Ungvari GS, Chiu 
HF, Wang YJ, Wang CX. The relationship between frontal lobe lesions, course of post-stroke 
depression, and 1-year prognosis in patients with first-ever ischemic stroke. PLoS One. [Research 
Support, Non-U.S. Gov't]. 2014;9:e100456. 
74. Hayee M, Akhtar N, Haque A, Rabbani M. Depression after stroke-analysis of 297 stroke 
patients. Bangladesh Med Res Counc Bull. 2001;27:96-102. 
75. Chausson N, Olindo S, Cabre P, Saint-Vil M, Smadja D. Five-Year Outcome of a Stroke Cohort 
in Martinique, French West Indies: Etude Réalisée en Martinique et Centrée sur l’Incidence des 
Accidents vasculaires cérebraux, Part 2. Stroke. 2010;41:594-9. 
76. Bacher Y, Korner-Bitensky N, Mayo N, Becker R. A longitudinal study of depression among 
stroke patients participating in a rehabilitation program. Can J Rehabil. 1990;4:27-37. 
77. Herrmann N, Black S, Lawrence J, Szekely C, Szalai J. The Sunnybrook stroke study: A 
prospective study of depressive symptoms and functional outcome. Stroke. 1998;29:618-24. 
78. Coyle MK. Depressive symptoms after a myocardial infarction and self-care. Arch Psychiatr 
Nurs. 2012;26:127-34. 
   
 
  21 
 
79. Lauzon C, Beck CA, Huynh T, Dion D, Racine N, Carignan S, Diodati JG, Charbonneau F, Dupuis 
R, Pilote L. Depression and prognosis following hospital admission because of acute myocardial 
infarction. CMAJ. 2003;168:547-52. 
80. Mallik S, Spertus JA, Reid KJ, Krumholz HM, Rumsfeld JS, Weintraub WS, Agarwal P, Santra M, 
Bidyasar S, Lichtman JH. Depressive symptoms after acute myocardial infarction: Evidence for highest 
rates in younger women. Arch Intern Med. 2006;166:876-83. 
81. Smolderen KG, Buchanan DM, Gosch K, Whooley MA, Chan PS, Vaccarino V, Parashar S, Shah 
AJ, Ho PM, Spertus JA. Depression treatment and 1-year mortality following acute myocardial 
infarction: Insights from the TRIUMPH registry. Circulation. 2017:CIRCULATIONAHA. 116.025140. 
82. Travella JI, Forrester AW, Schultz SK, Robinson RG. Depression following myocardial infarction: 
a one year longitudinal study. Int J Psychiatry Med. 1994;24:357-69. 
83. Larsen KK, Christensen B, Søndergaard J, Vestergaard M. Depressive symptoms and risk of 
new cardiovascular events or death in patients with myocardial infarction: A population-based 
longitudinal study examining health behaviors and health care interventions. PLoS One. 
2013;8:e74393. 
84. Spijkerman T, de Jonge P, van den Brink RH, Jansen JH, May JF, Crijns HJ, Ormel J. Depression 
following myocardial infarction: First-ever versus ongoing and recurrent episodes. Gen Hosp 
Psychiatry. 2005;27:411-7. 
85. Huffman JC, Mastromauro CA, Beach SR, Celano CM, DuBois CM, Healy BC, Suarez L, Rollman 
BL, Januzzi JL. Collaborative care for depression and anxiety disorders in patients with recent cardiac 
events: The Management of Sadness and Anxiety in Cardiology (MOSAIC) randomized clinical trial. 
JAMA Intern Med. 2014;174:927-35. 
86. Jorge RE, Robinson RG, Arndt S, Starkstein S. Mortality and poststroke depression: A placebo-
controlled trial of antidepressants. American Journal of Psychiatry. 2003;160:1823-9. 
87. Eriksson M, Asplund K, Glader E-L, Norrving B, Stegmayr B, Terént A, Åsberg KH, Wester P-O. 
Self-reported depression and use of antidepressants after stroke: A national survey. Stroke. 
2004;35:936-41. 
88. Gustafson Y, Nilsson I, Mattsson M, Åström M, Bucht G. Epidemiology and treatment of post-
stroke depression. Drugs Aging. 1995;7:298-309. 
89. Corrigan P. How stigma interferes with mental health care. Am Psychol. 2004;59:614-25. 
90. Simon GE, VonKorff M. Recognition, management, and outcomes of depression in primary 
care. Arch Fam Med. 1995;4:99-105. 
91. Mojtabai R, Olfson M, Mechanic D. Perceived need and help-seeking in adults with mood, 
anxiety, or substance use disorders. Arch Gen Psychiatry. 2002;59:77-84. 
 
